Mazur et al. reported that JQ1 + gemcitabine slowed tumor growth (P < 0.05) more than either drug as a single agent in GEM mutant Kras, p53 mice, and the combination increased duration of overall survival compared to control or gemcitabine only groups (P < 0.001) [28]. The gene discussed is KRAS; the disease is neoplasm.